Acro Biomedical (ACBM) Cost of Revenue (2017 - 2022)

Acro Biomedical has reported Cost of Revenue for 6 years, with the latest figure at $296000.0 in Q4 2022.

• For the quarter ending Q4 2022, Cost of Revenue fell 33.93% year-over-year to $296000.0; the trailing twelve-month figure through Sep 2023 stood at $296000.0 (down 55.82% YoY), and the FY2022 full-year result was $518000.0, down 44.78% from the prior year.
• Cost of Revenue for Q4 2022 stood at $296000.0, up from $222000.0 in the prior quarter.
• The five-year high for Cost of Revenue was $2.2 million in Q3 2018, with the low at $70000.0 in Q1 2021.
• Average Cost of Revenue over 5 years is $842290.9, with a median of $448000.0 recorded in 2021.
• Year-over-year, Cost of Revenue slumped 86.76% in 2021 and surged 217.14% in 2022.
• Tracing ACBM's Cost of Revenue over 5 years: stood at $1.2 million in 2018, then sank by 85.11% to $181440.0 in 2019, then surged by 191.31% to $528560.0 in 2020, then slipped by 15.24% to $448000.0 in 2021, then sank by 33.93% to $296000.0 in 2022.
• The last three Cost of Revenue figures came in at $296000.0 (Q4 2022), $222000.0 (Q1 2022), and $448000.0 (Q4 2021), per Business Quant data.

Peer Comparison